Clinical-pathological correlation of K-Ras mutation and ERK phosphorylation in colorectal cancer

Polish Journal of Pathology

Volumn 63, Issue 2, 2012, Pages 93-100

  Tai, Cheng Jeng ^a,b   Chang, Chun Chao ^a,b   Jiang, Ming Chung ^a   Yeh, Chung Min ^c,d   Su, Tzu Cheng ^c,d   Wu, Pei Ru ^c,d   Chen, Chih Jung ^c,d,e   Yeh, Kun Tu ^c,e,f   Lin, Shu Hui ^c,d   Chen, Hung Chang ^c  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^d JEN TEH JUNIOR COLLEGE OF MEDICINE   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^f KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Colorectal cancer; ERK; Mutation; Phosphorylation; Ras

Indexed keywords

MAPK1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE 1; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER STAGING; COLORECTAL TUMOR; DISEASE COURSE; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; ONCOGENE RAS; PATHOLOGY; PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MUTATION; NEOPLASM STAGING; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84864842724     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Wójcik P, Kulig J, Okoń K, et al. KRAS mutation profile in colorectal carcinoma and novel mutation-internal tandem duplication in KRAS. Pol J Pathol 2008; 59: 93-96.
2. Jiang Y, Kimchi ET, Staveley-O'Carroll KF, et al. Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer. Cancer 2009; 115: 3609-3617.
3. Wang HL, Lopategui J, Amin MB, et al. KRAS mutation testing in human cancers: The pathologist's role in the era of personalized medicine. Adv Anat Pathol 2010; 17: 23-32.
4. BarbacidM. ras genes. Annu Rev Biochem 1987; 56: 779-827.
5. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-4689.
6. Vaughn CP, Zobell SD, Furtado LV, et al. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 2011; 50: 307-312.
7. Ory S, Morrison DK. Signal transduction: implications for Rasdependent ERK signaling. Curr Biol 2004; 14: 277-278.
8. Hoshino R, Chatani Y, Yamori T, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999; 18: 813-822.
9. Wójcik P, Okoń K, Osuch C, et al. BRAF mutations in sporadic colorectal carcinoma from Polish patients. Pol J Pathol 2010; 61: 23-26.
10. Sakakura C, Hagiwara A, Shirahama T, et al. Infrequent activation of mitogen-activated protein kinase in human colon cancers. Hepatogastroenterology 1999; 46: 2831-2834.
11. Adler V, Pincus MR, Brandt-Rauf PW, et al. Complexes of p21RAS with JUN N-terminal kinase and JUN proteins. Proc Natl Acad Sci U S A 1995; 92: 10585-10589.
12. Castellano E, Downward J. RAS Interaction with PI3K: more than just another effector pathway. Genes Cancer 2011; 2: 261-274
13. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. (eds). Colon and rectum. In: AJCC cancer staging manual, 7th edition, Springer, New York 2009; 143-159.
14. Chang YS, Yeh KT, Chang TJ, et al. Fast simultaneous detection of K-RASmutations in colorectal cancer. BMC Cancer 2009; 9: e179.
15. Wang JY, Wang YH, Jao SW, et al. Molecular mechanisms underlying the tumorigenesis of colorectal adenomas: correlation to activated K-ras oncogene. Oncol Rep 2006; 16: 1245-1252.
16. Stefanius K, Ylitalo L, Tuomisto A, et al. Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma. Histopathology 2011; 58: 679-692.
17. Kwon MJ, Lee SE, Kang SY, et al. Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: Comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue. Pathol Res Pract 2011; 207: 762-768.
18. Schmitz KJ, Wohlschlaeger J, Alakus H, et al. Activation of extracellular regulated kinases (ERK1/2) but not AKT predicts poor prognosis in colorectal carcinoma and is associated with k-ras mutations. Virchows Arch 2007; 450: 151-159.
19. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009; 9: 537-549.
20. Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 2011; 36: 320-328.
21. Huang C, Ma WY, Li J, Goranson A, et al. Requirement of Erk, but not JNK, for arsenite-induced cell transformation. J Biol Chem 1999; 274: 14595-14601.
22. Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 2010; 1802: 396-405.
23. Levidou G, Saetta AA, Gigelou F, et al. ERK/pERK expression, B-raf and K-ras mutations in colon adenocarcinomas: correlation with clinicopathological characteristics and expression of hMLH1 and hMSH2.World J Surg Oncol 2012; 10: e47.
24. Zeng M, Kikuchi H, Pino MS, et al. Hypoxia activates the K-ras proto-oncogene to stimulate angiogenesis and inhibit apoptosis in colon cancer cells. PLoS One 2010; 5: e10966.
25. Losi L, Ponti G, Gregorio CD, et al. Prognostic significance of histological features and biological parameters in stage I (pT1 and pT2) colorectal adenocarcinoma. Pathol Res Pract 2006; 202: 663-670.
26. Ozgüven BY, Karaçetin D, Kabukçuoǧlu F, et al. Immunohistochemical study of E-cadherin and β-catenin expression in colorectal carcinomas. Pol J Pathol 2011; 62: 19-24.